N ext-generation healthcare company Prime Medicine (NASDAQ: PRME) was exactly what the doctor ordered for ailing portfolios ...

Prime Medicine and Bristol Myers Squibb are collaborating on next-generation ex vivo T-cell therapies. Read more here.

Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...

Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime ...

Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Stifel Nicolaus analyst Dae Gon Ha maintained a Hold rating on Prime Medicine, Inc. (PRME – Research Report) today. The company’s ...

Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more ...

Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is ...

Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company ...

Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, ...

RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.

Consumer staples shares jumped by 0.3% on Monday. In trading on Monday, materials shares fell by 0.6%. In commodity news, oil ...